Vineet LaboratoriesVINEETLAB 
-0.82%24h
Vineet Laboratories (VINEETLAB) Stock Overview
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients and fine chemicals in India. It offers intermediates of lopinavir, ritonavir, efavirenz, nadolol, glimepiride, celecoxib, olanine, and other API intermediates; and fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.
VINEETLAB Stock Information
Vineet Laboratories (VINEETLAB) Price Chart
Vineet Laboratories Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $0.7181448401817774 | N/A |
| Market Cap | $6.62M | N/A |
| Shares Outstanding | 9.22M | 0.00% |
| Employees | 72.00 | N/A |
| Shareholder Equity | 336.83M | 1.40% |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | 0.53 | N/A |
| P/S Ratio | 0.26 | N/A |
| P/B Ratio | 0.02 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | 0.0004 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $25.31M | N/A |
| Earnings | $149.32K | N/A |
| EPS | 1.36 | N/A |
| Earnings Yield | 1.89 | N/A |
| Gross Margin | 0.1401 | N/A |
| Operating Margin | 0.0265 | N/A |
| Net income margin | 0.0059 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $13.81M | N/A |
| Total Debt | $3.71M | N/A |
| Cash on Hand | $112.86K | N/A |
| Debt to Equity | 0.0291 | -19.05% |
| Cash to Debt | 0.0305 | -94.84% |
| Current Ratio | $1.17 | 8.31% |
